Canada approves use of Johnson & Johnson's single-shot Covid-19 vaccine

Representative Image

Canada announced its approval of the use of the single-shot Johnson & Johnson Covid-19 vaccine, making it the fourth vaccine that can be administered in the country.

"After a thorough, independent review of the evidence, the Department has determined that the vaccine meets Canada's stringent safety, efficacy and quality requirements," Health Canada said in a statement on Friday, Xinhua news agency reported.

The approval is expected to provide a significant boost to Canada's vaccine rollout. Johnson & Johnson's vaccine is widely seen as one of the easiest to administer because it requires only one dose and can be stored for long periods of time at regular refrigerator temperatures.

The US healthcare giant's vaccine is the fourth to be approved in Canada. Earlier, Canada approved the use of Pfizer-BioNTech, Moderna and AstraZeneca vaccines.

"Canada is the first country to approve four vaccines," said Dr. Supriya Sharma, Health Canada's chief medical advisor, at a press conference Friday morning.

It is approved in Canada for use in individuals aged 18 and older.

Canada has been assessing the Johnson & Johnson shot since November 30 last year.

It has ordered 10 million doses from Johnson & Johnson with options for up to 28 million more. Most of those shots are expected to arrive by the end of September this year.

--IANS

int/


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel